Global Latent Tuberculosis Infection Detection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Latent Tuberculosis Infection Detection Market Research Report 2024
The main ways to diagnose LTBI are by placing a tuberculin skin test (TST) on the forearm or by getting a TB blood test, in addition to obtaining a chest radiograph (x-ray) if either one of these tests is positive. One-third of the world's population has LTBI. The TB germs are dormant (asleep) in the body.
According to MRAResearch’s new survey, global Latent Tuberculosis Infection Detection market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Latent Tuberculosis Infection Detection market research.
Key companies engaged in the Latent Tuberculosis Infection Detection industry include Abbott, QIAGEN, F. Hoffmann-La Roche Ltd, Sanofi, Oxford Immunotec USA, ARKRAY, Inc. and bioMérieux SA, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Latent Tuberculosis Infection Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Latent Tuberculosis Infection Detection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Latent Tuberculosis Infection Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott
QIAGEN
F. Hoffmann-La Roche Ltd
Sanofi
Oxford Immunotec USA
ARKRAY, Inc.
bioMérieux SA
Segment by Type
Tuberculin Skin Test
Interferon Gamma Release Assays
Diagnostic Laboratories
Hospitals/Clinics
Academic & Research Institutions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Latent Tuberculosis Infection Detection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Latent Tuberculosis Infection Detection market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Latent Tuberculosis Infection Detection market research.
Key companies engaged in the Latent Tuberculosis Infection Detection industry include Abbott, QIAGEN, F. Hoffmann-La Roche Ltd, Sanofi, Oxford Immunotec USA, ARKRAY, Inc. and bioMérieux SA, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Latent Tuberculosis Infection Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Latent Tuberculosis Infection Detection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Latent Tuberculosis Infection Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott
QIAGEN
F. Hoffmann-La Roche Ltd
Sanofi
Oxford Immunotec USA
ARKRAY, Inc.
bioMérieux SA
Segment by Type
Tuberculin Skin Test
Interferon Gamma Release Assays
Segment by Application
Diagnostic Laboratories
Hospitals/Clinics
Academic & Research Institutions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Latent Tuberculosis Infection Detection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source